Pfizer received U.S. FDA Emergency Use Authorization for novel COVID-19 oral antiviral treatment
On Dec. 22, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had authorized the emergency…
-
-
USDA confirmed COVID-19 in a Canada lynx at a Pennsylvania zoo
On Dec. 21, 2021, the United States Department of Agriculture’s (USDA) National Veterinary Services Laboratories announced confirmation of…
-
European Commission granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
-
Oragenics extended collaboration with the National Research Council of Canada (NRC) to develop vaccine against Omicron variant
On Dec. 20, 2021, Oragenics announced it had extended a licensing and collaboration agreement with the National Research…
-
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
-
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
-
Twist Bioscience began shipping synthetic RNA positive controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 variant for Development of Accurate Diagnostic Tests
On Dec. 15, 2021, Twist Bioscience announced that synthetic RNA positive controls were available for the SARS-CoV-2 Omicron…
-
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
-
CEPI partnered with Affinivax to develop a novel COVID-19 vaccine to target variants
On Dec. 13, 2021, the Coalition for Epidemic Preparedness Innovations, and Affinivax announced a partnership to advance the…
-
FDA authorized long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals
On Dec. 8, 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZenecaﾒs Evusheld…
-
Pfizer and BioNTech provided update on Omicron variant
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
-
PerkinElmer launched NEXTFLEX variant-Seq SARS-CoV-2 kit v2 to strengthen SARS-CoV-2 surveillance
On Dec. 8, 2021, PerkinElmer announced the research use only launch of the NEXTFLEXﾮ Variant-Seqﾙ SARS-CoV-2 Kit v2…
-
Arbutus Biopharma, X-Chem and Proteros biostructures achieved first milestone under COVID-19 discovery research
On Dec. 7, 2021, Arbutus Biopharma, X-Chem, and Proteros announced that Arbutus had identified several molecules that inhibit…
-
Llama antibodies could help fight SARS-CoV-2 variants
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
-
Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
-
Roche announced the launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark
On Dec. 5, 2021, Roche announced that its planned to launch the SARS-CoV-2 & Flu A/B Rapid Antigen…
-
Roche announced additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant
On Dec. 3, 2021, Roche and TIB Molbiol announced they had added three additional Research Use Only test…
-
Fulgent Genetics confirmed ability to detect Omicron variant with RT-PCR tests for COVID-19
On Dec. 1, 2021, Fulgent Genetics confirmed that the Companyﾒs RT-PCR test for SARS-CoV-2, the virus that causes…
-
T2 Biosystems T2SARS-CoV-2 panel detected Omicron variant
On Dec. 1, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected the Omicron COVID-19 variant (B.1.1.529). The…
-
INOVIO Announced Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
On Nov. 30, 2021, Inovio Pharma announced the company was rapidly moving to evaluate its COVID-19 DNA vaccine…
-
Thermo Fisher Scientific confirmed detection of SARS-CoV-2 in samples containing Omicron Variant with TaqPath COVID-19 tests
On Nov. 29, 2021, Thermo Fisher Scientific confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit…
-
Hologic’s COVID-19 tests detected Omicron variant
On Nov. 29, 2021, Hologic announced that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of…
-
Merck and Ridgeback Biotherapeutics provided update on results from MOVe-OUT study of Molnupiravir in adults with COVID-19
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
-
WHO announced classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern
On Nov. 26, 2021, the World Health Organization announced that the Technical Advisory Group on SARS-CoV-2 Virus Evolution…
-
WHO and Medicines Patent Pool announced first transparent, global, non-exclusive licence for COVID-19 technology
On Nov. 23, 2021, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized…
-
Tonix Pharmaceuticals announced publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
-
FDA announced FDA authorization of Moderna’s booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
-
Pfizer provided U.S. Government with 10 million treatment courses of oral antiviral candidate to help combat COVID-19
On Nov. 18, 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses…
-
Pfizer submitted Emergency Use Authorization for novel COVID-19 oral antiviral candidate
On Nov. 16, 2021, Pfizer announced it had submitted an Emergency Use Authorization (EUA) of its investigational oral…
-
Meridian Bioscience received FDA Emergency Use Authorization for Revogeneﾮ SARS-CoV-2 molecular assay
On Nov. 10, 2021, Meridian Bioscience announced that their Revogeneﾮ SARS-CoV-2 assay was granted Emergency Use Authorization by…
